PDE5A and pulmonary arterial hypertension: Data on breastfeeding in patients using PAH therapy are limited; there are no clear recommendations, although there are reports in which there are patients undergoing PAH-targeted therapy with PDE5 inhibitors or parenteral prostacyclins breastfeeding without any known complications [51].